Promotion of ROS-mediated apoptosis, G2/M arrest, and autophagy by naringenin in non-small cell lung cancer

Tsung-Ming Chang1,2, Miao-Ching Chi3,4,5,6, Yao-Chang Chiang3,7

  • 1School of Dental Technology, College of Oral Medicine, Taipei Medical University, Taipei 11031, Taiwan.

Insights

Naringenin, a natural compound, effectively kills lung cancer cells by inducing cell cycle arrest, apoptosis, and autophagy. This study reveals naringenin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading global cause of cancer mortality.
  • Naringenin, a flavanone, exhibits anti-cancer and anti-inflammatory properties.
  • Naringenin has shown cytotoxic effects on various cancer cell types.

Purpose of the Study:

  • To investigate the molecular mechanisms of naringenin-induced cell death in lung cancer.
  • To evaluate the anti-cancer effects of naringenin in vitro and in vivo.
  • To explore naringenin's potential as a small-molecule drug for lung cancer treatment.

Main Methods:

  • Assessed apoptosis, cell cycle arrest, and autophagy markers using TUNEL, Western blot, Annexin V/PI, PI staining, acridine orange, and TEM.
  • Utilized fluorescence microscopy, DALGreen, and GFP-LC3 plasmids to evaluate autophagy flux and puncta formation.
  • Evaluated naringenin's anti-cancer efficacy in a subcutaneous H1299 cell xenograft mouse model.

Main Results:

  • Naringenin reduced lung cancer cell viability and induced cell cycle arrest.
  • Naringenin triggered apoptosis and autophagy via ROS generation and AMPK activation.
  • Naringenin suppressed tumor growth and promoted apoptosis in a mouse model.

Conclusions:

  • Naringenin demonstrates potent anti-cancer effects against lung cancer cells.
  • Naringenin induces cell death through apoptosis, cell cycle arrest, and autophagy.
  • Naringenin holds promise as a therapeutic agent for lung cancer.